Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)

被引：0
|
作者：
Olasehinde, Temitope [1 ]
Cooper, Gregory [1 ]
Perez, Jaime A. [1 ]
机构：
[1] Case Western Reserve Univ, Univ Hosp, Cleveland Med Ctr, Dept Neurol, Cleveland, OH USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001031256.48901.46
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S472
引用
收藏
页码：S329 / S330
页数：2
相关论文
共 50 条
  • [21] Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
    Dankner, Rachel
    Murad, Havi
    Agay, Nirit
    Olmer, Liraz
    Freedman, Laurence S.
    JAMA NETWORK OPEN, 2024, 7 (01) : E2350408
  • [22] Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus
    Davis, Portia N.
    Ndefo, Uche Anadu
    Oliver, Ashley
    Payton, Enryka
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (13) : 1097 - 1103
  • [23] THE UNSEEN CONSEQUENCES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) IN PATIENTS UNDERGOING UPPER ENDOSCOPY
    Chapman, Malcolm
    Norwood, Dalton
    Price, Christopher
    Abdulhadi, Basma
    Rapaka, Babusai
    Baig, Kondal Kyanam Kabir
    Ahmed, Ali
    Peter, Shajan
    Routman, Justin
    Duggan, Elizabeth
    Sanchez-Luna, Sergio A.
    Mulki, Ramzi
    GASTROINTESTINAL ENDOSCOPY, 2024, 99 (06) : AB421 - AB422
  • [24] Use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in dialysis patients
    Pelz, Stefan
    Schwarz, Albin
    Ambuhl, Patrice
    SWISS MEDICAL WEEKLY, 2020, : 38S - 38S
  • [25] Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP-1RA) in PatientS with Type 2 Diabetes-PROGRESS-DIABETES Study
    Brown, Ruth E.
    Abitbol, Alexander
    Bajaj, Harpreet S.
    Khandwala, Hasnain
    Goldenberg, Ronald
    Abdel-Salam, Suzan
    Aronson, Ronnie
    DIABETES, 2018, 67
  • [26] Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)
    Singhal, Mukul
    Tan, Hiangkiat
    Coleman, Craig I.
    Herman, William H.
    Cai, Jennifer
    Han, Michelle
    Ingham, Mike
    DIABETES, 2018, 67
  • [27] Efficacy and safety of Glucagon-like peptide-1 receptor agonist (GLP-1RA) plus basal insulin versus basal insulin in Type 2 Diabetes Mellitus: A Systematic review and Meta-analysis
    Conboy, M.
    Houlihan, C.
    O'Brien, T.
    Liew, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S372 - S372
  • [28] DUAL THERAPY WITH METFORMIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1-RA) REDUCES COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS AND CIRRHOSIS
    Huynh, Daniel J.
    Renelus, Benjamin D.
    Jamorabo, Daniel S.
    GASTROENTEROLOGY, 2023, 164 (06) : S1340 - S1341
  • [29] Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
    Pierre Gourdy
    Patrice Darmon
    François Dievart
    Jean-Michel Halimi
    Bruno Guerci
    Cardiovascular Diabetology, 22
  • [30] Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
    Gourdy, Pierre
    Darmon, Patrice
    Dievart, Francois
    Halimi, Jean-Michel
    Guerci, Bruno
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
12345